Novo Nordisk initiates trial with obesity-treating tablet
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12919926.ece/ALTERNATES/schema-16_9/doc7fgbgyy1b681iht8o96h.jpg)
Novo Nordisk plans to initiate a new phase IIIa trial program against obesity with the firm's molecule semaglutide, according to a press release on Wednesday afternoon.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.